A new AbbVie study published in the NEJM reports a 30mg dose of upadacitinib is superior to adalimumab in...
New AbbVie study reports upadacitinib is superior to adalimumab
read more
Celltrion received a positive CHMP opinion for Remsima® subcut (subcutaneous infliximab)
Celltrion received a positive CHMP opinion for Remsima® subcut (subcutaneous infliximab). Remsima® SC was recommended...
STADA launches Oyavas® (biosimilar bevacizumab) in the Netherlands and Germany
STADA launched Oyavas® (biosimilar bevacizumab) in the Netherlands and Germany. Oyavas® is indicated for carcinoma of...
Samsung Bioepis launches Hadlima® (biosimilar adalimumab) in Australia and Canada
Samsung Bioepis announced on 29 March 2021 that it has launched Hadlima®, its 50mg/mL biosimilar adalimumab in...
Alvotech denies AbbVie’s claims of trade secret piracy
Alvotech has disputed AbbVie's claim filed in the Northern District of Illinois last week relating to AbbVie's...
AU’s PBAC makes changes to adalimumab listings
A number of changes have been made to the PBS listings of adalimumab. From 1 April: The Amgen, Merck/Samsung, Sandoz...
LG Chem receives approval for its biosimilar adalimumab in Japan
Korea Biomedical Review reported that LG Chem has received approval from Japan's Health Ministry for its biosimilar...
mAbxience announces new 4,000L CSR bioreactor
mAbxience announced it will install an ABEC 4,000L CSR bioreactor at its site in Leon, Spain. The system is expected...
EirGenix announced positive Ph III results for trastuzumab biosimilar
EirGenix announced that its Ph III clinical trial of EG12014 (proposed trastuzumab biosimilar) has met its primary...
Herzuma® gains 44% market share in Japan
The Korea Herald reported that Celltrion's Herzuma® (biosimilar trastuzumab) reached a 44% market share in Japan last...
Pfizer to sell Chinese manufacturing site
Reuters reported that Pfizer will stop producing biosimilar products in China and will sell an intended manufacturing...
Merck announces formation of new spin-off Organon
Merck announced it has filed a Form 10 registration statement with the US Securities and Exchange Commission in...
Alvotech completes second round of private placement
Alvotech announced it has completed a second round of its US$100 million private placement. In the first round,...
Samsung Bioepis enters biosimilar adalimumab agreement with Yuhan
Korea Biomedical Review reported that Samsung Bioepis has entered an agreement with Yuhan Corp for the...
US Senate passes two pieces of biosimilar legislation
The US Senate unanimously passed the Ensuring Innovation Act and the Advancing Education on Biosimilars Act. The...
Lannett provides update on insulin glargine biosimilar
Lannett announced it had received comments from the FDA related to the pivotal trial protocol and statistical analysis...